Goodman & Gilman's The Pharmacological Basis of Therapeutics

Last updated

Goodman & Gilman's The Pharmacological Basis of Therapeutics, commonly referred to as the Blue Bible or Goodman & Gilman, is a textbook of pharmacology originally authored by Louis S. Goodman and Alfred Gilman. First published in 1941, the book is in its thirteenth edition (as of 2017), and has the reputation of being the "bible of pharmacology". The readership of this book include physicians of all therapeutic and surgical specialties, clinical pharmacologists, clinical research professionals and pharmacists.

Contents

While teaching jointly in the Yale School of Medicine's Department of Pharmacology, Goodman and Gilman began developing a course textbook that emphasized relationships between pharmacodynamics and pharmacotherapy, introduced recent pharmacological advances like sulfa drugs, and discussed the history of drug development. [1] [2] Yale physiologist John Farquhar Fulton encouraged them to publish the work for a broader audience and introduced them to a publisher at the Macmillan Publishing Company. [1] Their new text was first published in 1941 under the title The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Student. [1] Because the volume was twice as long as a typical textbook, Macmillan printed few copies, but demand for a readable, up-to-date pharmacological text proved high, and several printings followed. [2]

Although rapid pharmacological innovations were made in the years immediately following—including the introduction of chemotherapy, steroids, antibiotics, and antihistamines—a second edition could not be completed until 1955 because of the authors' service in World War II. [2] [1] Thereafter, the text was revised every five years in collaboration with a large number of specialist coauthors. [1]

Gilman and Goodman remained the book's lead editors for the first five editions; Gilman remained an editor through the sixth edition, and Goodman through the seventh, which was published shortly after Gilman's death in 1984. Alfred Goodman Gilman, the son of Alfred Gilman and winner of the 1994 Nobel Prize in Medicine and Physiology, joined as senior editor for the book's sixth, seventh, and eighth editions, and a contributing editor to the ninth and tenth. [3] Goodman died in 2000, and Goodman Gilman in December 2015.

Editions

Editions 1-5

The first five editions were published under the title The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology, and Therapeutics for Physicians and Medical Students.

Editions 6 onwards

Editions 6 onwards were published under the title Goodman & Gilman's The Pharmacological Basis of Therapeutics.

Reviews

There have been many published book reviews of this widely used textbook. The first edition reviewer was highly enthusiastic and said that he was “delirious in his appraisal of the book”, that it was an “amazing work”, and “the product of enormous industry and keen insight”. [4] A reviewer of the eighteen-hundred page second-edition described it as encyclopedic, indispensable, and as an excellent resource for students. [5] The fourth edition reviewer noted that “all other related books seem to pale by comparison”. [6] The 6th edition published in 1980 was praised for the extensive bibliography, but also noted that, although “this book is recommended to all those who prescribe drugs”, it had become “too large to be used by medical students as a routine textbook”. [7] The ninth edition was designated as the "blue bible of pharmacology" and as the gold standard. [8] The 12th edition was criticized for only one-ninth of authors being female. [9] However, this had increased to one-fifth of the authors being female in the thirteen-edition. A policy of the editors has been to not disclose the potential conflicts of interest by the authors. The 12th edition authors were the recipients of over one-hundred and thirty patents. [10] The thirteenth edition authors received three-million dollars from pharmaceutical companies which was undisclosed. Unlike earlier editions which were praised for being up to date, [4] an analysis of the 13th edition found that the citations were older than those of other pharmacology textbooks. [9] A team of the reviewers for the 2018 edition were more measured than those of earlier editions. [9]

Related Research Articles

<span class="mw-page-title-main">Glimepiride</span> Group of stereoisomers

Glimepiride, is an anti-diabetic medication used to treat type 2 diabetes. It is less preferred than metformin. Use is recommended together with diet and exercise. It is taken by mouth. Glimepiride takes up to three hours for maximum effect and lasts for about a day.

The melanocyte-stimulating hormones, known collectively as MSH, also known as melanotropins or intermedins, are a family of peptide hormones and neuropeptides consisting of α-melanocyte-stimulating hormone (α-MSH), β-melanocyte-stimulating hormone (β-MSH), and γ-melanocyte-stimulating hormone (γ-MSH) that are produced by cells in the pars intermedia of the anterior lobe of the pituitary gland.

An osmotic diuretic is a type of diuretic that inhibits reabsorption of water and sodium (Na). They are pharmacologically inert substances that are given intravenously. They increase the osmolarity of blood and renal filtrate.

<span class="mw-page-title-main">Alfred G. Gilman</span> American pharmacologist

Alfred Goodman Gilman was an American pharmacologist and biochemist. He and Martin Rodbell shared the 1994 Nobel Prize in Physiology or Medicine "for their discovery of G-proteins and the role of these proteins in signal transduction in cells."

<span class="mw-page-title-main">Ciliary muscle</span> Eye muscle which is used for focussing

The ciliary muscle is an intrinsic muscle of the eye formed as a ring of smooth muscle in the eye's middle layer, uvea. It controls accommodation for viewing objects at varying distances and regulates the flow of aqueous humor into Schlemm's canal. It also changes the shape of the lens within the eye but not the size of the pupil which is carried out by the sphincter pupillae muscle and dilator pupillae.

<span class="mw-page-title-main">Gonadorelin</span> Chemical compound

Gonadorelin is a gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. It is also used in veterinary medicine. The medication is a form of the endogenous GnRH and is identical to it in chemical structure. It is given by injection into a blood vessel or fat or as a nasal spray.

Hiram Houston Merritt Jr. was one of the pre-eminent academic neurologists of his day. He was chair of the Neurological Institute of New York and Neurologist-in-Chief of NewYork-Presbyterian Hospital / Columbia University Medical Center in the Washington Heights neighborhood of Manhattan, New York City.

Butyrophenone is an organic compound with the formula C6H5C(O)C3H7. It is a colorless liquid.

<span class="mw-page-title-main">Morphinan</span> Chemical compound

Morphinan is the prototype chemical structure of a large chemical class of psychoactive drugs, consisting of opiate analgesics, cough suppressants, and dissociative hallucinogens, among others.

A nicotinic antagonist is a type of anticholinergic drug that inhibits the action of acetylcholine (ACh) at nicotinic acetylcholine receptors. These compounds are mainly used for peripheral muscle paralysis in surgery, the classical agent of this type being tubocurarine, but some centrally acting compounds such as bupropion, mecamylamine, and 18-methoxycoronaridine block nicotinic acetylcholine receptors in the brain and have been proposed for treating nicotine addiction.

Adrenergic means "working on adrenaline (epinephrine) or noradrenaline (norepinephrine)". When not further qualified, it is usually used in the sense of enhancing or mimicking the effects of epinephrine and norepinephrine in the body.

<span class="mw-page-title-main">Senna glycoside</span>

Senna glycoside, also known as sennoside or senna, is a medication used to treat constipation and empty the large intestine before surgery. The medication is taken by mouth or via the rectum. It typically begins working in around 30 minutes when given by rectum and within twelve hours when given by mouth. It is a weaker laxative than bisacodyl or castor oil.

<span class="mw-page-title-main">Coronary stent</span> Medical apparatus implanted into coronary arteries

A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open in the treatment of coronary heart disease. It is used in a procedure called percutaneous coronary intervention (PCI). Coronary stents are now used in more than 90% of PCI procedures. Stents reduce angina and have been shown to improve survivability and decrease adverse events in an acute myocardial infarction.

<span class="mw-page-title-main">Alfred Gilman Sr.</span> American pharmacologist

Alfred Zack Gilman was an American pharmacologist best known for pioneering early chemotherapy techniques using nitrogen mustard with his colleague, Louis S. Goodman. The pair also published the classic textbook The Pharmacological Basis of Therapeutics in 1941, and Gilman served as an editor for its first six editions. Gilman served on the faculties of the Yale School of Medicine, the Columbia College of Physicians and Surgeons, and the Albert Einstein College of Medicine, where he founded the Department of Pharmacology. He was a member of U.S. National Academy of Sciences.

<span class="mw-page-title-main">Levallorphan</span> Opioid medication

Levallorphan, also known as levallorphan tartrate (USAN), is an opioid modulator of the morphinan family used as an opioid analgesic and opioid antagonist/antidote. It acts as an antagonist of the μ-opioid receptor (MOR) and as an agonist of the κ-opioid receptor (KOR), and as a result, blocks the effects of stronger agents with greater intrinsic activity such as morphine whilst simultaneously producing analgesia.

<span class="mw-page-title-main">Norepinephrine releasing agent</span> Catecholaminergic type of drug

A norepinephrine releasing agent (NRA), also known as an adrenergic releasing agent, is a catecholaminergic type of drug that induces the release of norepinephrine (noradrenaline) and epinephrine (adrenaline) from the pre-synaptic neuron into the synapse. This in turn leads to increased extracellular concentrations of norepinephrine and epinephrine therefore an increase in adrenergic neurotransmission.

In toxicology, the median toxic dose (TD50) of a drug or toxin is the dose at which toxicity occurs in 50% of cases. The type of toxicity should be specified for this value to have meaning for practical purposes. The median toxic dose encompasses the category of toxicity that is greater than half maximum effective concentration (ED50) but less than the median lethal dose (LD50). However, for some highly potent toxins (ex. lofentanil, botulinum toxin) the difference between the ED50 and TD50 is so minute that the values assigned to them may be approximated to equal doses. Since toxicity need not be lethal, the TD50 is generally lower than the median lethal dose (LD50), and the latter can be considered an upper bound for the former. However, since the toxicity is above the effective limit, the TD50 is generally greater than the ED50. If the result of a study is a toxic effect that does not result in death, it is classified as this form of toxicity. Toxic effects can be defined differently, sometimes considering the therapeutic effect of a substance to be toxic (such as with chemotherapeutics) which can lead to confusion and contention regarding a substance's TD50. Examples of these toxic endpoints include cancer, blindness, anemia, and birth defects.

<span class="mw-page-title-main">Louis S. Goodman</span> American pharmacologist

Louis Sanford Goodman was an American pharmacologist. He is best known for his collaborations with Alfred Gilman, Sr., with whom he authored the popular textbook The Pharmacological Basis of Therapeutics in 1941 and pioneered the first chemotherapy trials using nitrogen mustard.

<span class="mw-page-title-main">Enasidenib</span>

Enasidenib is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development.

<span class="mw-page-title-main">Normustine</span> Nitrogen mustard used as a chemotherapy agent

Normustine, also known as bis(2-chloroethyl)carbamic acid, is a nitrogen mustard and alkylating antineoplastic agent. It is a metabolite of a number of antineoplastic agents that have been developed for the treatment of tumors, including estramustine phosphate, alestramustine, cytestrol acetate, and ICI-85966 (stilbostat), but only the former of which has actually been marketed.

References

  1. 1 2 3 4 5 Ritchie, Murdoch (1996). A Biographical Memoir of Albert Gilman (PDF). National Academies Press. pp. 60–63. Retrieved 26 March 2015.
  2. 1 2 3 Altman, Lawrence K. (28 November 2000). "Dr. Louis S. Goodman, 94, Chemotherapy Pioneer, Dies". New York Times. Retrieved 25 March 2015.
  3. Hastings, R. C. (1996). "Goodman and Gilman's the Pharmacological Basis of Therapeutics". JAMA: The Journal of the American Medical Association. 276 (12): 71–72. doi:10.1001/jama.1996.03540120077042. PMC   2590057 .
  4. 1 2 Dameshek, W. The Pharmacological Basis of Therapeutics. Yale J. Biol. Med. 1941, 13, 558–559.
  5. Davies, J.E. The Pharmacological Basis of Therapeutics, 2nd ed. J. Am. Dent. Soc. Anesthesiol. 1958, 5, 30–31.
  6. Lowell, R.J. The Pharmaceutical Basis of Therapeutics, 4th ed. Anesth Prog. 1971, 18, 19.
  7. Stout, R.W. The Pharmacological Basis of Therapeutics. Ulster Med. J. 1981, 50, 68.
  8. Hastings, R.C.; Long, G.W. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. JAMA J. Am. Med. Assoc. 1996, 276, 999–1000.
  9. 1 2 3 Piper, B.J.; Telku, H.M.; Lambert, D.A. A quantitative analysis of undisclosed conflicts of interest in pharmacology textbooks. PLoS ONE 2015, 10, e0133261.
  10. Casavant, M.J. Goodman and Gilman’s Pharmacological Basis of Therapeutics. JAMA J. Am. Med. Assoc. 2002, 288, 2052.